Swissmedic-Aligned Compendial Testing for Advanced Therapy Medicinal Products (ATMPs)

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Swissmedic-Aligned Compendial Testing for Advanced Therapy Medicinal Products (ATMPs)

Swissmedic-Aligned Compendial Testing for Viral Vector ATMPs

CELL & GENE | RNA | BIOLOGICS

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

Proven Intelligence Accelerating Next-Generation Therapies.

Characterization & Compliance for European Market Access.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Executive Summary

The framework for compendial testing of viral vector-based Advanced Therapy Medicinal Products (ATMPs) intended for Swissmedic submission details the required assays for ensuring product safety, purity, and quality. It aligns with European Pharmacopoeia (Ph. Eur.) monographs and provides a clear testing strategy for AAV, Lentivirus, and Adenovirus vectors to support successful Investigational Medicinal Product Dossier (IMPD) submissions.

Frequently Asked Questions

    What are compendial assays for viral vectors?

    Compendial assays are standardized analytical tests defined by a pharmacopoeia, such as the European Pharmacopoeia (Ph. Eur.) or United States Pharmacopeia (USP). For viral vectors, these tests primarily assess safety attributes like sterility, mycoplasma, endotoxin levels, and the absence of adventitious agents.

    Why is pharmacopoeia alignment important for a Swissmedic submission?

    Swissmedic, like other major regulatory bodies, expects ATMP submissions to demonstrate adherence to established quality standards. Aligning with Ph. Eur. monographs provides a recognized benchmark for product safety and control, streamlining the review of an IMPD submission.

    Which specific tests are required for ATMP release?

    Core release tests include sterility testing (Ph. Eur. 2.6.1), mycoplasma detection (Ph. Eur. 2.6.7), and bacterial endotoxin testing (Ph. Eur. 2.6.14). Additional assays for adventitious agents and product-specific attributes are also necessary.

    How does Franklin Biolabs ensure GxP compliance for these assays?

    All compendial testing is performed within a robust quality system that adheres to GxP principles. Assays are conducted using qualified equipment and validated methods, with full documentation to support regulatory filings. This is managed within our >100,000 sq ft facility, designed to support programs on an 18-24 month timeline to IND.

The Role of Compendial Methods in ATMP Characterization

Compendial testing forms the backbone of any robust CMC analytical strategy for viral vectors. These established methods provide the definitive data on product safety required by regulatory authorities. While novel, product-specific assays are needed to define identity and potency, pharmacopoeial tests are the universal standard for confirming a product is free from microbial and process-related contaminants.

Accurate execution of these tests requires a deep understanding of the viral vector modality. The testing strategy must account for the unique biological properties of AAV, lentiviral, or adenoviral vectors to ensure results are accurate and interpretable.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Navigating Swissmedic and European Pharmacopoeia Requirements

For sponsors targeting the European market, including Switzerland, alignment with the European Pharmacopoeia is a baseline expectation. An IMPD submitted to Swissmedic must contain a comprehensive data package demonstrating control over the manufacturing process and final product.

The value of standardized resources in advancing therapeutic programs is well-documented. The framework established by programs like the NHLBI GTRP demonstrates that access to high-quality, consistent analytical support accelerates the path to clinical testing (PMID: 23692378). Applying this principle, we utilize harmonized compendial methods to generate data that is immediately recognizable and acceptable to European regulators.

Core Compendial Assays for Viral Vector Products

A successful analytical control strategy for viral vectors incorporates a panel of compendial tests applied at different stages of the manufacturing process. Rapid Assay Development Accelerating Quality Control ensures that these methods are implemented efficiently to provide timely data for process decisions and batch release.

  • Sterility (Ph. Eur. 2.6.1): Confirms the absence of viable bacteria and fungi in the final drug product.

  • Mycoplasma (Ph. Eur. 2.6.7): Detects contamination from mycoplasma, a common cell culture contaminant that is not visible by standard microscopy.

  • Bacterial Endotoxins (Ph. Eur. 2.6.14): Quantifies endotoxins from Gram-negative bacteria to prevent pyrogenic responses.

  • Adventitious Agent Testing: A broader set of assays to ensure the product is free from extraneous viruses introduced via raw materials or the manufacturing process.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Infrastructure for Programmatic Support

Delivering a comprehensive testing package requires significant infrastructure and operational expertise. The analytical laboratories must be equipped and operated under GxP conditions to ensure data integrity for regulatory submissions.

Learn more about the infrastructure required for next-generation therapeutics in the full video, .

Our approach, which has contributed to a 100% successful IND rate for programs we have supported since 2019, is built on this foundation. Franklin Biolabs, launched in 2024, inherits this legacy of scientific and regulatory execution.

Technical Visualization: Compendial Testing Workflow for Viral Vector Release

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities